Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 37, 2022 - Issue 1
Submit an article Journal homepage
2,811
Views
29
CrossRef citations to date
0
Altmetric
Research Papers

Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies

Mohammed S. Taghoura Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, EgyptView further author information
,
Hazem Elkadya Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, EgyptView further author information
,
Wagdy M. Eldehnab Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt;c School of Biotechnology, Badr University in Cairo, Badr City, Cairo, EgyptView further author information
,
Nehal M. El-Deebd Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, EgyptView further author information
,
Ahmed M. Kenawye Nucleic Acids Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, EgyptView further author information
,
Eslam B. Elkaeedf Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, Saudi ArabiaView further author information
,
Aisha A. Alsfoukg Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi ArabiaORCID Iconhttps://orcid.org/0000-0003-4497-5013View further author information
ORCID Icon,
Mohamed S. Alesawya Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, EgyptView further author information
,
Ahmed M. Metwalyd Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria, Egypt;h Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, EgyptCorrespondence[email protected]
View further author information
&
Ibrahim. H. Eissaa Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, EgyptCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6955-2263View further author information
ORCID Icon show all
Pages 1903-1917 | Received 18 Mar 2022, Accepted 29 May 2022, Published online: 08 Jul 2022

References

  • Abd El-Mageed MM, Eissa AA, Farag AE-S, Osman EEA. Design and synthesis of novel furan, furo [2, 3-d] pyrimidine and furo [3, 2-e][1, 2, 4] triazolo [1, 5-c] pyrimidine derivatives as potential VEGFR-2 inhibitors. Bioorg Chem 2021;116:105336.
  • El-Sayed AA, Nossier ES, Almehizia AA, Amr AE-GE. Design, synthesis, anticancer evaluation and molecular docking study of novel 2, 4-dichlorophenoxymethyl-based derivatives linked to nitrogenous heterocyclic ring systems as potential CDK-2 inhibitors. J Mol Struct 2022;1247:131285.
  • Chaudhari P, Bari S, Surana S, et al. Logical synthetic strategies and structure-activity relationship of indolin-2-one hybrids as small molecule anticancer agents: an overview. J Mol Struct 2022;1247:131280.
  • Parmar DR, Soni JY, Guduru R, et al. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorg Chem 2021;115:105206.
  • Alsaif NA, Taghour MS, Alanazi MM, et al. Identification of new [1, 2, 4] triazolo [4, 3-a] quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: design, synthesis, anticancer evaluation, and in silico studies. Bioorg Med Chem 2021;46:116384.
  • Elrazaz EZ, Serya RA, Ismail NS, et al. Discovery of potent thieno [2, 3-d] pyrimidine VEGFR-2 inhibitors: design, synthesis and enzyme inhibitory evaluation supported by molecular dynamics simulations. Bioorg Chem 2021;113:105019.
  • Mohamed TK, Batran RZ, Elseginy SA, et al. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis. Bioorg Chem 2019;85:253–73.
  • Mahdy HA, Ibrahim MK, Metwaly AM, et al. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4 (3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg Chem 2020;94:103422.
  • Guo S, Colbert LS, McGlothen TZ, Gonzalez-Perez RR. Regulation of angiogenesis in human cancer via vascular endothelial growth factor receptor-2 (VEGFR-2). Tumor Angiogenesis 2012;2012:27–66.
  • Modi SJ, Kulkarni VM. Vascular endothelial growth factor receptor (VEGFR-2)/KDR inhibitors: medicinal chemistry perspective. Med Drug Discovery 2019;2:100009.
  • Huang Y, Chen X, Dikov MM, et al. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood J Am Soc Hematol 2007;110:624–31.
  • Machado VA, Peixoto D, Costa R, et al. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg Med Chem 2015;23:6497–509.
  • Wang Z, Wang N, Han S, et al. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One 2013;8:e68566.
  • Dietrich J, Hulme C, Hurley LH. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796. Bioorg Med Chem 2010;18:5738–48.
  • Xie Q-Q, Xie H-Z, Ren J-X, et al. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. J Mol Graph Model 2009;27:751–8.
  • Lee K, Jeong K-W, Lee Y, et al. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur J Med Chem 2010;45:5420–7.
  • Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol 2014;132:496–505.
  • Abdel-Aziz HA, Ghabbour HA, Eldehna WM, et al. Synthesis, crystal structure, and biological activity of cis/trans amide rotomers of (Z)-N′-(2-Oxoindolin-3-ylidene) formohydrazide. J Chem 2014;2014:1–7.
  • Eldehna WM, Al-Wabli RI, Almutairi MS, et al. Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents. J Enzyme Inhib Med Chem 2018;33:867–78.
  • Attia MI, Eldehna WM, Afifi SA, et al. New hydrazonoindolin-2-ones: synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres. PloS One 2017;12:e0181241.
  • Mohamady S, Galal M, Eldehna WM, et al. Dual targeting of VEGFR2 and C-met kinases via the design and synthesis of substituted 3-(Triazolo-thiadiazin-3-yl) indolin-2-one derivatives as angiogenesis inhibitors. ACS Omega 2020;5:18872–86.
  • Eldehna WM, Abo-Ashour MF, Al-Warhi T, et al. Development of 2-oxindolin-3-ylidene-indole-3-carbohydrazide derivatives as novel apoptotic and anti-proliferative agents towards colorectal cancer cells. J Enzyme Inhib Med Chem 2021;36:320–9.
  • Prakash CR, Raja S. Indolinones as promising scaffold as kinase inhibitors: a review. Mini Rev Med Chem 2012;12:98–119.
  • Zou H, Zhang L, Ouyang J, et al. Synthesis and biological evaluation of 2-indolinone derivatives as potential antitumor agents. Eur J Med Chem 2011;46:5970–7.
  • Fang Y, Wu Z, Xiao M, et al. Design, synthesis, and evaluation of new 2-oxoquinoline arylaminothiazole derivatives as potential anticancer agents. Bioorg Chem 2021;106:104469.
  • Bonnefous C, Payne JE, Roppe J, et al. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. J Med Chem 2009;52:3047–62.
  • Ohashi T, Oguro Y, Tanaka T, et al. Discovery of pyrrolo [3, 2-c] quinoline-4-one derivatives as novel hedgehog signaling inhibitors. Bioorg Med Chem 2012;20:5496–506.
  • Suthar SK, Jaiswal V, Lohan S, et al. Novel quinolone substituted thiazolidin-4-ones as anti-inflammatory, anticancer agents: design, synthesis and biological screening. Eur J Med Chem 2013;63:589–602.
  • Banu S, Bollu R, Bantu R, et al. Design, synthesis and docking studies of novel 1, 2-dihydro-4-hydroxy-2-oxoquinoline-3-carboxamide derivatives as a potential anti-proliferative agents. Eur J Med Chem 2017;125:400–10.
  • Yu Y-C, Kuang W-B, Huang R-Z, et al. Design, synthesis and pharmacological evaluation of new 2-oxo-quinoline derivatives containing α-aminophosphonates as potential antitumor agents. MedChemComm 2017;8:1158–72.
  • Shankar S, Vuppu S. In vitro drug metabolism and pharmacokinetics of a novel thiazolidinedione derivative, a potential anticancer compound. J Pharma Biomed Anal 2020;179:113000.
  • Sharma P, Reddy TS, Kumar NP, et al. Conventional and microwave-assisted synthesis of new 1H-benzimidazole-thiazolidinedione derivatives: a potential anticancer scaffold. Eur J Med Chem 2017;138:234–45.
  • Joshi H, Patil V, Tilekar K, et al. Benzylidene thiazolidinediones: synthesis, in vitro investigations of antiproliferative mechanisms and in vivo efficacy determination in combination with Imatinib. Bioorg Med Chem Lett 2020;30:127561.
  • Alsaif NA, Taghour MS, Alanazi MM, et al. Discovery of new VEGFR-2 inhibitors based on bis ([1, 2, 4] triazolo)[4, 3-a: 3′, 4′-c] quinoxaline derivatives as anticancer agents and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1093–114.
  • Alanazi MM, Eissa IH, Alsaif NA, et al. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1760–82.
  • Abdallah AE, Alesawy MS, Eissa SI, et al. Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: molecular modeling and in vitro antiviral screening. New J Chem 2021;45:16557–71.
  • Alanazi MM, Elkady H, Alsaif NA, et al. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies. RSC Adv 2021;11:30315–28.
  • Alsaif NA, Dahab MA, Alanazi MM, et al. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: design, molecular modeling, and synthesis. Bioorg Chem 2021;110:104807.
  • El-Metwally SA, Abou-El-Regal MM, Eissa IH, et al. Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorg Chem 2021;112:104947.
  • Alanazi MM, Elkady H, Alsaif NA, et al. Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: design, synthesis, and in silico study. J Mol Struct 2022;1253:132220.
  • Elkady H, Elwan A, El-Mahdy HA, et al. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. J Enzyme Inhib Med Chem 2022;37:397–410.
  • El-Zahabi MA, Sakr H, El-Adl K, et al. Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorg Chem 2020;104:104218.
  • Laxmikeshav K, Kumari P, Shankaraiah N. Expedition of sulfur‐containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: a decade update. Med Res Rev 2022;42:513–75.
  • Yadav U, Vanjari Y, Laxmikeshav K, et al. Synthesis and in vitro cytotoxicity evaluation of phenanthrene linked 2, 4-thiazolidinediones as potential anticancer agents. Anti-Cancer Agents Med Chem 2021;21:1127–40.
  • Tokala R, Thatikonda S, Sana S, et al. Synthesis and in vitro cytotoxicity evaluation of β-carboline-linked 2, 4-thiazolidinedione hybrids: potential DNA intercalation and apoptosis-inducing studies. New J Chem 2018;42: 16226–36.
  • Sharma P, Reddy TS, Thummuri D, et al. Synthesis and biological evaluation of new benzimidazole-thiazolidinedione hybrids as potential cytotoxic and apoptosis inducing agents. Eur J Med Chem 2016;124:608–21.
  • Hou T, Zhu L, Chen L, Xu X. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies. J Chem Inform Comput Sci 2003;43:273–87.
  • Kar K, Krithika U, Basu P, et al. Design, synthesis and glucose uptake activity of some novel glitazones. Bioorg Chem 2014;56:27–33.
  • Abdel-Wahab BF, Khidre RE. 2-Chloroquinoline-3-carbaldehyde II: synthesis, reactions, and applications. J Chem 2013;2013:1–13.
  • Bruno G, Costantino L, Curinga C, et al. Synthesis and aldose reductase inhibitory activity of 5-arylidene-2, 4-thiazolidinediones. Bioorg Med Chem 2002;10:1077–84.
  • Evdokimov NM, Magedov IV, McBrayer D, Kornienko A. Isatin derivatives with activity against apoptosis-resistant cancer cells. Bioorg Med Chem Lett 2016;26:1558–60.
  • Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
  • Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271–7.
  • Thabrew M, Hughes RD, Mcfarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol 2011;49:1132–5.
  • Pritchett JC, Naesens L, Montoya J. Treating HHV-6 infections: the laboratory efficacy and clinical use of ati-HHV-6 agents. 7th edition; 2014. Pages 311–331.
  • Peña-Morán OA, Villarreal ML, Álvarez-Berber L, et al. Cytotoxicity, post-treatment recovery, and selectivity analysis of naturally occurring podophyllotoxins from Bursera fagaroides var. fagaroides on breast cancer cell lines. Molecules 2016;21:1013.
  • Indrayanto G, Putra GS, Suhud F. Validation of in-vitro bioassay methods: application in herbal drug research. Profiles Drug Subst Excip Related Methodol 2021;46:273–307.
  • Liang C-C, Park AY, Guan J-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature Protocols 2007;2:329–33.
  • D’Anselmi F, Valerio M, Cucina A, et al. Metabolism and cell shape in cancer: a fractal analysis. Int J Biochem Cell Biol 2011;43:1052–8.
  • Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 2005;333:336–43.
  • Yang J, Song K, Krebs TL, et al. Rb/E2F4 and Smad2/3 link survivin to TGF-β-induced apoptosis and tumor progression. Oncogene 2008;27:5326–38.
  • El-Helby A-GA, Ayyad RR, El-Adl K, Elkady H. Phthalazine-1, 4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking. Mol Divers 2019;23:283–98.
  • El‐Helby AGA, Ayyad RR, Zayed MF, et al. Design, synthesis, in silico ADMET profile and GABA‐A docking of novel phthalazines as potent anticonvulsants. Archiv Der Pharmazie 2019;352:1800387.
  • Sousa SF, Fernandes PA, Ramos MJ. Protein–ligand docking: current status and future challenges. Proteins: Struct Funct Bioinform 2006;65:15–26.
  • Hollingsworth SA, Dror RO. Molecular dynamics simulation for all. Neuron 2018;99:1129–43.
  • Hansson T, Oostenbrink C, van Gunsteren W. Molecular dynamics simulations. Curr Opin Struct Biol 2002;12:190–6.
  • Durrant JD, McCammon JA. Molecular dynamics simulations and drug discovery. BMC Biol 2011;9:71–9.
  • Miller BR, III, McGee TD, Jr, Swails JM, et al. MMPBSA. PY: an efficient program for end-state free energy calculations. J Chem Theory Comput 2012;8:3314–21.
  • Wang E, Sun H, Wang J, et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev 2019;119:9478–508.
  • Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 2015;10:449–61.
  • Hou T, Wang J, Li Y, Wang W. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Informat Model 2011;51:69–82.
  • Xia X, Maliski EG, Gallant P, Rogers D. Classification of kinase inhibitors using a Bayesian model. J Med Chem 2004;47:4463–70.
  • BIOVIA QSAR, ADMET and predictive toxicology. https://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/qsar-admet-and-predictive-toxicology.html [last accessed May 2020].
  • El-Deeb NM, Ibrahim OM, Mohamed MA, et al. Alginate/κ-carrageenan oral microcapsules loaded with Agaricus bisporus polysaccharides MH751906 for natural killer cells mediated colon cancer immunotherapy. Int J Biol Macromol 2022;205:385–95.
  • Abou-Seri SM, Eldehna WM, Ali MM, Abou El Ella DA. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: synthesis and in vitro biological evaluation. Eur J Med Chem 2016;107:165–79.
  • Borenfreund E, Puerner JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 1985;24:119–24.
  • Koch A, Tamez P, Pezzuto J, Soejarto D. Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. J Ethnopharmacol 2005;101:95–99.
  • Arranz-Valsero I, Soriano-Romaní L, García-Posadas L, et al. IL-6 as a corneal wound healing mediator in an in vitro scratch assay. Exp Eye Res 2014;125:183–92.
  • Zucchini N, de Sousa G, Bailly-Maitre B, et al. Regulation of Bcl-2 and Bcl-xL anti-apoptotic protein expression by nuclear receptor PXR in primary cultures of human and rat hepatocytes. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 2005;1745:48–58.
  • El-Zahabi MA, Elbendary ER, Bamanie FH, et al. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of phthalimide-sulfonylurea hybrids as PPARγ and SUR agonists. Bioorg Chem 2019;91:103115.
  • Ibrahim MK, Eissa IH, Alesawy MS, et al. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4 (3H)-one derivatives as potential PPARγ and SUR agonists. Bioorg Med Chem 2017;25:4723–44.
  • Ibrahim MK, Eissa IH, Abdallah AE, et al. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ and SUR agonists. Biorg Med Chem 2017;25:1496–513.
  • El-Gamal KM, El-Morsy AM, Saad AM, et al. Synthesis, docking, QSAR, ADMET and antimicrobial evaluation of new quinoline-3-carbonitrile derivatives as potential DNA-gyrase inhibitors. J Mol Struct 2018;1166:15–33.
  • Elkaeed EB, Elkady H, Belal A, et al. Multi-phase in silico discovery of potential SARS-CoV-2 RNA-dependent rna polymerase inhibitors among 3009 clinical and FDA-approved related drugs. Processes 2022;10:530.
  • Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for Charmm. J Comput Chem 2008;29:1859–65.
  • Brooks BR, Brooks CL, III, Mackerell AD, Jr, et al. CHARMM: the biomolecular simulation program. J Comput Chem 2009;30:1545–614.
  • Lee J, Cheng X, Swails JM, et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. J Chem Theory Comput 2016;12:405–13.
  • Best RB, Zhu X, Shim J, et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles. J Chem Theory Comput 2012;8:3257–73.
  • Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Computat Chem 2005;26:1781–802.
  • Suleimen YM, Jose RA, Suleimen RN, et al. Jusanin, a new flavonoid from Artemisia commutata with an in silico inhibitory potential against the SARS-CoV-2 main protease. Molecules 2022;27:1636.
  • Suleimen YM, Jose RA, Suleimen RN, et al. Isolation and in silico anti-SARS-CoV-2 Papain-like protease potentialities of two rare 2-phenoxychromone derivatives from Artemisia spp. Molecules 2022;27:1216.
  • Mohammed SO, El Ashry ESH, Khalid A, et al. Expression, purification, and comparative inhibition of helicobacter pylori urease by regio-selectively alkylated benzimidazole 2-thione derivatives. Molecules 2022;27:865.
  • Alesawy MS, Elkaeed EB, Alsfouk AA, et al. In silico screening of semi-synthesized compounds as potential inhibitors for SARS-CoV-2 papain-like protease: pharmacophoric features, molecular docking, ADMET, toxicity and DFT studies. Molecules 2021;26:6593.
  • El-Adl K, Ibrahim M-K, Alesawy MS, Eissa IH. [1, 2, 4] Triazolo [4, 3-c] quinazoline and bis ([1, 2, 4] triazolo)[4, 3-a: 4′, 3′-c] quinazoline derived DNA intercalators: design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies. Bioorg Med Chem 2021;30:115958.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.